Effects of antipsychotics on the BDNF in schizophrenia

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 345-350

  Huang, T L ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acetylation; Brain derived neurotrophic factor; Methylation; Schizophrenia; Suicide antipsychotics

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ACETYLATION; ANTERIOR CINGULATE; ANTIPSYCHOTIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL FEATURE; DRUG ABUSE; DRUG EFFECT; DRUG RESPONSE; DRUG THERAPY; EPIGENETICS; GENOTYPE; HAPLOTYPE; HIPPOCAMPUS; HISTONE MODIFICATION; NERVE CELL PLASTICITY; OCCIPITAL CORTEX; ONSET AGE; PARANOID SCHIZOPHRENIA; PARIETAL CORTEX; PHENOTYPE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; PROTEIN METHYLATION; RESIDUAL SCHIZOPHRENIA; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

EID: 84877978387     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320030004     Document Type: Article

References (100)

1. Benes, F.M., Neurobiological investigations in cingulate cortex of schizophrenic brain. Schizophr Bull, 1993, 19, (3), 537-549. (Pubitemid 23272621)
2. Waddington, J.L., Schizophrenia: developmental neuroscience and pathobiology. Lancet, 1993, 341, (8844), 531-536. (Pubitemid 23066096)
3. Weinberger, D.R., From neuropathology to neurodevelopment. Lancet, 1995, 346, (8974), 552-557.
4. Nawa, H.; Takahashi, M.; Patterson, P.H., Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry, 2000, 5, (6), 594-603.
5. Ashe, P.C.; Berry, M.D.; Boulton, A.A., Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol Biol Psychiatry, 2001, 25, (4), 691-707. (Pubitemid 32374963)
6. Nawa, H.; Bessho, Y.; Carnahan, J.; Nakanishi, S.; Mizuno, K., Regulation of neuropeptide expression in cultured cerebral cortical neurons by brainderived neurotrophic factor. J Neurochem, 1993, 60, (2), 772-775. (Pubitemid 23030982)
7. Mizuno, K.; Carnahan, J.; Nawa, H., Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol, 1994, 165, (1), 243-256. (Pubitemid 24306118)
8. Nawa, H.; Pelleymounter, M.A.; Carnahan, J., Intraventricular administration of BDNF increases neuropeptide expression in newborn rat brain. J Neurosci, 1994, 14, (6), 3751-3765. (Pubitemid 24174121)
9. Segal, R.A.; Pomeroy, S.L.; Stiles, C.D., Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci, 1995, 15, (7 Pt 1), 4970-4981.
10. Segal, R.A.; Rua, L.; Schwartz, P., Neurotrophins and programmed cell death during cerebellar development. Adv Neurol, 1997, 72, 79-86.
11. Ferrer, I.; Ballabriga, J.; Marti, E.; Perez, E.; Alberch, J.; Arenas, E., BDNF up-regulates TrkB protein and prevents the death of CA1 neurons following transient forebrain ischemia. Brain Pathol, 1998, 8, (2), 253-261. (Pubitemid 28186063)
12. Xiong, H.; Yamada, K.; Han, D.; Nabeshima, T.; Enikolopov, G.; Carnahan, J.; Nawa, H., Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons. Eur J Neurosci, 1999, 11, (5), 1567-1576. (Pubitemid 29192231)
13. Egan, M.F.; Kojima, M.; Callicott, J.H.; Goldberg, T.E.; Kolachana, B.S.; Bertolino, A.; Zaitsev, E.; Gold, B.; Goldman, D.; Dean, M.; Lu, B.; Weinberger, D.R., The BDNF val66met polymorphism affects activitydependent secretion of BDNF and human memory and hippocampal function. Cell, 2003, 112, (2), 257-269. (Pubitemid 36144114)
14. Frost, D.O.; Tamminga, C.A.; Medoff, D.R.; Caviness, V.; Innocenti, G.; Carpenter, W.T., Neuroplasticity and schizophrenia. Biol Psychiatry, 2004, 56, (8), 540-543. (Pubitemid 39336400)
15. Neves-Pereira, M.; Cheung, J.K.; Pasdar, A.; Zhang, F.; Breen, G.; Yates, P.; Sinclair, M.; Crombie, C.; Walker, N.; St Clair, D.M., BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry, 2005, 10, (2), 208-212. (Pubitemid 40188515)
16. Buckley, P.F.; Mahadik, S.; Pillai, A.; Terry, A., Jr., Neurotrophins and schizophrenia. Schizophr Res, 2007, 94, (1-3), 1-11. (Pubitemid 47033973)
17. Xu, M.Q.; St Clair, D.; Feng, G.Y.; Lin, Z.G.; He, G.; Li, X.; He, L., BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics, 2008, 18, (6), 449-457. (Pubitemid 351769923)
18. Xu, M.; Li, S.; Xing, Q.; Gao, R.; Feng, G.; Lin, Z.; St Clair, D.; He, L., Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study. Eur J Hum Genet, 2010, 18, (6), 707-712.
19. Fusar-Poli, P.; Bonoldi, I.; Yung, A.R.; Borgwardt, S.; Kempton, M.J.; Valmaggia, L.; Barale, F.; Caverzasi, E.; McGuire, P., Predicting Psychosis: Meta-Analysis of Transition Outcomes in Individuals at High Clinical Risk. Arch Gen Psychiatry, 2012, 69, (3), 220-229.
20. Fusar-Poli, P.; Bechdolf, A.; Taylor, M.; Bonoldi, I.; Carpenter, W.; Yung, A.; McGuire, P., At risk for schizophrenic or affective psychosis? A metaanalysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr Bull, 2012, in press.
21. Fusar-Poli, P.; Borgwardt, S.; Bechdolf, A.; Addington, J.; Riecher-Rössler, A.; Schultze-Lutter, F.; Keshavan, M.; Wood, S.; Ruhrmann, S.; Seidman, L.; Valmaggia, L.; Cannon, T.; Velthorst, E.; De Haan, L.; Cornblatt, B.; Birchwood, M.; McGlashan, T.; Carpenter, W.; McGorry, P.; Klosterkötter, J.; McGuire, P.; Yung, A., The psychosis high risk state: a comprehensive state of the art review Arch Gen Psychiatry. Arch Gen Psychiatry, 2012, in press.
22. Fusar-Poli, P.; Deste, G.; Smieskova, R.; Barlati, G.; Yung, A.R.; Howes, O.; Stieglitz, R.; McGuire, P.; Borgwardt, S., Cognitive functioning in prodromal psychosis: a meta-Analysis. Arch Gen Psychiatry, 2012, in press.
23. Fusar-Poli, P.; Borgwardt, S.; Crescini, A.; Deste, G.; Kempton, M.J.; Lawrie, S.; Mc Guire, P.; Sacchetti, E., Neuroanatomy of vulnerability to psychosis: a voxel-based meta-Analysis. Neurosci Biobehav Rev, 2011, 35, (5), 1175-1185.
24. Fusar-Poli, P.; Radua, J.; McGuire, P.; Borgwardt, S., Neuroanatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. Schizophr Bull, 2011.
25. Fusar-Poli, P.; Perez, J.; Broome, M.; Borgwardt, S.; Placentino, A.; Caverzasi, E.; Cortesi, M.; Veggiotti, P.; Politi, P.; Barale, F.; McGuire, P., Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-Analysis. Neurosci Biobehav Rev, 2007, 31, (4), 465-484. (Pubitemid 46527879)
26. Crossley, N.A.; Mechelli, A.; Fusar-Poli, P.; Broome, M.R.; Matthiasson, P.; Johns, L.C.; Bramon, E.; Valmaggia, L.; Williams, S.C.; McGuire, P.K., Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp, 2009, 30, (12), 4129-4137.
27. Fusar-Poli, P.; Stone, J.M.; Broome, M.R.; Valli, I.; Mechelli, A.; McLean, M.A.; Lythgoe, D.J.; O'Gorman, R.L.; Barker, G.J.; McGuire, P.K., Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry, 2011, 68, (9), 881-890.
28. Fusar-Poli, P.; Howes, O.D.; Allen, P.; Broome, M.; Valli, I.; Asselin, M.C.; Grasby, P.M.; McGuire, P.K., Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry, 2010, 67, (7), 683-691.
29. Fusar-Poli, P.; Howes, O.D.; Allen, P.; Broome, M.; Valli, I.; Asselin, M.C.; Montgomery, A.J.; Grasby, P.M.; McGuire, P., Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry, 2011, 16, (1), 67-75.
30. Fusar-Poli, P.; Meyer-Lindenberg, A., Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies. Schizophr Bull, 2012.
31. Smieskova, R.; Fusar-Poli, P.; Allen, P.; Bendfeldt, K.; Stieglitz, R.D.; Drewe, J.; Radue, E.W.; McGuire, P.K.; Riecher-Rossler, A.; Borgwardt, S.J., Neuroimaging predictors of transition to psychosis-A systematic review and meta-Analysis. Neurosci Biobehav Rev, 2010, 34, (8), 1207-1222.
32. Fusar-Poli, P.; Yung, A.R., Should attenuated psychosis syndrome be included in DSM-5? Lancet, 2012, 379, (9816), 591-592.
33. Preti, A.; Cella, M., Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res, 2010, 123, (1), 30-36.
34. Rosa, A.; Cuesta, M.J.; Fatjo-Vilas, M.; Peralta, V.; Zarzuela, A.; Fananas, L., The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am J Med Genet B Neuropsychiatr Genet, 2006, 141B, (2), 135-138. (Pubitemid 43214787)
35. Rizos, E.N.; Siafakas, N.; Stefanis, N.; Douzenis, A.; Kontaxakis, V.; Laskos, E.; Kastania, A.; Zoumbourlis, V.; Lykouras, L., Association of serum BDNF and val66met polymorphism of the brain-derived neurotrophic factor in a sample of first psychotic episode patients. Psychiatrike, 2009, 20, (4), 297-304.
36. Decoster, J.; van Os, J.; Kenis, G.; Henquet, C.; Peuskens, J.; De Hert, M.; van Winkel, R., Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet, 2011, 156B, (3), 363-369.
37. Grillo, R.W.; Ottoni, G.L.; Leke, R.; Souza, D.O.; Portela, L.V.; Lara, D.R., Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res, 2007, 41, (1-2), 31-35. (Pubitemid 44708213)
38. Pirildar, S.; Gonul, A.S.; Taneli, F.; Akdeniz, F., Low serum levels of brainderived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry, 2004, 28, (4), 709-713. (Pubitemid 38987396)
39. Tan, Y.L.; Zhou, D.F.; Cao, L.Y.; Zou, Y.Z.; Zhang, X.Y., Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett, 2005, 382, (1-2), 27-32.
40. Toyooka, K.; Asama, K.; Watanabe, Y.; Muratake, T.; Takahashi, M.; Someya, T.; Nawa, H., Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res, 2002, 110, (3), 249-257. (Pubitemid 34804533)
41. Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Cao, L.Y.; Wu, G.Y.; Xu, Q.; Shen, Y.; Haile, C.N.; Kosten, T.A.; Kosten, T.R., Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. J Psychiatr Res, 2007, 41, (12), 997-1004. (Pubitemid 47304448)
42. Lee, A.H.; Lange, C.; Ricken, R.; Hellweg, R.; Lang, U.E., Reduced brainderived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol, 2011, 31, (3), 334-336.
43. Huang, T.L.; Lee, C.T., Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res, 2006, 40, (7), 664-668.
44. Shimizu, E.; Hashimoto, K.; Watanabe, H.; Komatsu, N.; Okamura, N.; Koike, K.; Shinoda, N.; Nakazato, M.; Kumakiri, C.; Okada, S.; Iyo, M., Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett, 2003, 351, (2), 111-114. (Pubitemid 37329601)
45. Crow, T.J., Molecular pathology of schizophrenia: more than one disease process? Br Med J, 1980, 280, (6207), 66-68. (Pubitemid 10199277)
46. Kendler, K.S.; Karkowski-Shuman, L.; O'Neill, F.A.; Straub, R.E.; MacLean, C.J.; Walsh, D., Resemblance of psychotic symptoms and syndromes in affected sibling pairs from the Irish Study of High-Density Schizophrenia Families: evidence for possible etiologic heterogeneity. Am J Psychiatry, 1997, 154, (2), 191-198. (Pubitemid 27053724)
47. DeLisi, L.E.; Bass, N.; Boccio, A.; Shields, G.; Morganti, C., Age of onset in familial schizophrenia. Arch Gen Psychiatry, 1994, 51, (4), 334-335.
48. Kendler, K.S.; Tsuang, M.T.; Hays, P., Age at onset in schizophrenia. A familial perspective. Arch Gen Psychiatry, 1987, 44, (10), 881-890. (Pubitemid 17155446)
49. Huang, T.L.; Liou, C.W.; Lin, T.K., Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. Psychiatry Res, 2010, 177, (1-2), 18-21.
50. Ikeda, Y.; Yahata, N.; Ito, I.; Nagano, M.; Toyota, T.; Yoshikawa, T.; Okubo, Y.; Suzuki, H., Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res, 2008, 101, (1-3), 58-66.
51. Xiu, M.H.; Hui, L.; Dang, Y.F.; Hou, T.D.; Zhang, C.X.; Zheng, Y.L.; Chen da, C.; Kosten, T.R.; Zhang, X.Y., Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33, (8), 1508-1512.
52. Rizos, E.N.; Rontos, I.; Laskos, E.; Arsenis, G.; Michalopoulou, P.G.; Vasilopoulos, D.; Gournellis, R.; Lykouras, L., Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, (5), 1308-1311.
53. Rizos, E.N.; Papadopoulou, A.; Laskos, E.; Michalopoulou, P.G.; Kastania, A.; Vasilopoulos, D.; Katsafouros, K.; Lykouras, L., Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry, 2010, 11, (2 Pt 2), 251-255.
54. Elfving, B.; Plougmann, P.H.; Muller, H.K.; Mathe, A.A.; Rosenberg, R.; Wegener, G., Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol, 2010, 13, (5), 563-572.
55. Karege, F.; Schwald, M.; Cisse, M., Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett, 2002, 328, (3), 261-264. (Pubitemid 34876661)
56. Pan, W.; Banks, W.A.; Fasold, M.B.; Bluth, J.; Kastin, A.J., Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology, 1998, 37, (12), 1553-1561. (Pubitemid 28550429)
57. Durany, N.; Michel, T.; Zochling, R.; Boissl, K.W.; Cruz-Sanchez, F.F.; Riederer, P.; Thome, J., Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res, 2001, 52, (1-2), 79-86. (Pubitemid 32947050)
58. Takahashi, M.; Shirakawa, O.; Toyooka, K.; Kitamura, N.; Hashimoto, T.; Maeda, K.; Koizumi, S.; Wakabayashi, K.; Takahashi, H.; Someya, T.; Nawa, H., Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry, 2000, 5, (3), 293-300. (Pubitemid 30438405)
59. Wong, J.; Hyde, T.M.; Cassano, H.L.; Deep-Soboslay, A.; Kleinman, J.E.; Weickert, C.S., Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience, 2010, 169, (3), 1071-1084.
60. Pedrini, M.; Chendo, I.; Grande, I.; Lobato, M.I.; Belmonte-de-Abreu, P.S.; Lersch, C.; Walz, J.; Kauer-Sant'anna, M.; Kapczinski, F.; Gama, C.S., Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett, 2011, 491, (3), 207-210.
61. Huang, T.L.; Lee, C.T., Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatric Res, 2006, 40, (5), 664-668.
62. Chen, C.C.; Huang, T.L., Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res, 2011, 189, (3), 327-330.
63. Gonzalez-Pinto, A.; Mosquera, F.; Palomino, A.; Alberich, S.; Gutierrez, A.; Haidar, K.; Vega, P.; Barbeito, S.; Ortiz, A.; Matute, C., Increase in brainderived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol, 2010, 25, (4), 241-245.
64. Yoshimura, R.; Ueda, N.; Hori, H.; Ikenouchi-Sugita, A.; Umene-Nakano, W.; Nakamura, J., Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry, 2010, 11, (2 Pt 2), 256-261.
65. Hori, H.; Yoshimura, R.; Yamada, Y.; Ikenouchi, A.; Mitoma, M.; Ida, Y.; Nakamura, J., Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol, 2007, 22, (1), 21-27. (Pubitemid 44950764)
66. Lee, B.H.; Kim, Y.K., Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology, 2009, 59, (1), 51-58.
67. Yoshimura, R.; Hori, H.; Sugita, A.; Ueda, N.; Kakihara, S.; Umene, W.; Nakano, Y.; Shinkai, K.; Mitoma, M.; Ohta, M.; Shinkai, T.; Nakamura, J., Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4- hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, (5), 1072-1077. (Pubitemid 46810098)
68. Arranz, M.J.; de Leon, J., Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry, 2007, 12, (8), 707-747. (Pubitemid 47172693)
69. Guillin, O.; Demily, C.; Thibaut, F., Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol, 2007, 78, 377-395.
70. Chlan-Fourney, J.; Ashe, P.; Nylen, K.; Juorio, A.V.; Li, X.M., Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res, 2002, 954, (1), 11-20. (Pubitemid 35223437)
71. Lommatzsch, M.; Zingler, D.; Schuhbaeck, K.; Schloetcke, K.; Zingler, C.; Schuff-Werner, P.; Virchow, J.C., The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging, 2005, 26, (1), 115-123. (Pubitemid 39600596)
72. Webster, M.J.; Herman, M.M.; Kleinman, J.E.; Shannon Weickert, C., BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr Patterns, 2006, 6, (8), 941-951. (Pubitemid 44309446)
73. Gama, C.S.; Berk, M.; Andreazza, A.C.; Kapczinski, F.; Belmonte-de-Abreu, P., Serum levels of brain-derived neurotrophic factor and thiobarbituric acid reactive substances in chronically medicated schizophrenic patients: a positive correlation. Rev Bras Psiquiatr, 2008, 30, (4), 337-340.
74. Manji, H.K.; Duman, R.S., Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull, 2001, 35, (2), 5-49.
75. Duman, R.S., Synaptic plasticity and mood disorders. Mol Psychiatry, 2002, 7 Suppl 1, S29-34. (Pubitemid 34280646)
76. Pillai, A., Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS One, 2008, 3, (3), e1784.
77. Pillai, A., Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals, 2008, 16, (2-3), 183-193. (Pubitemid 351263224)
78. Dwivedi, Y., Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat, 2009, 5, 433-449.
79. Hung, Y.Y.; Lin, C.J.; Huang, T.L., Higher serum tropomyosin-related kinase B protein level in major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2010, 34, (4), 610-612.
80. Huang, T.L.; Hung, Y.Y.; Lee, C.T.; Chen, R.F., Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology, 2012, 65, (2), 65-69.
81. Angelucci, F.; Mathe, A.A.; Aloe, L., Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res, 2000, 60, (6), 783-794. (Pubitemid 30399550)
82. Lipska, B.K.; Khaing, Z.Z.; Weickert, C.S.; Weinberger, D.R., BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci, 2001, 14, (1), 135-144. (Pubitemid 32738482)
83. Linden, A.M.; Vaisanen, J.; Lakso, M.; Nawa, H.; Wong, G.; Castren, E., Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci, 2000, 14, (1-2), 27-37. (Pubitemid 30368297)
84. Pillai, A.; Terry, A.V., Jr.; Mahadik, S.P., Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res, 2006, 82, (1), 95-106. (Pubitemid 43202652)
85. Hong, C.J.; Liu, H.C.; Liu, T.Y.; Lin, C.H.; Cheng, C.Y.; Tsai, S.J., Brainderived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci Lett, 2003, 353, (1), 75-77.
86. Anttila, S.; Illi, A.; Kampman, O.; Mattila, K.M.; Lehtimaki, T.; Leinonen, E., Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm, 2005, 112, (7), 885-890. (Pubitemid 40869077)
87. Liou, Y.J.; Liao, D.L.; Chen, J.Y.; Wang, Y.C.; Lin, C.C.; Bai, Y.M.; Yu, S.C.; Lin, M.W.; Lai, I.C., Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med, 2004, 5, (3), 243-251.
88. Krebs, M.O.; Guillin, O.; Bourdell, M.C.; Schwartz, J.C.; Olie, J.P.; Poirier, M.F.; Sokoloff, P., Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry, 2000, 5, (5), 558-562.
89. Zhang, X.Y.; Zhou, D.F.; Wu, G.Y.; Cao, L.Y.; Tan, Y.L.; Haile, C.N.; Li, J.; Lu, L.; Kosten, T.A.; Kosten, T.R., BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology, 2008, 33, (9), 2200-2205. (Pubitemid 351992089)
90. Chao, H.M.; Kao, H.T.; Porton, B., BDNF Val66Met variant and age of onset in schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2008, 147B, (4), 505-506. (Pubitemid 351830812)
91. Lane, H.Y.; Liu, Y.C.; Huang, C.L.; Chang, Y.C.; Wu, P.L.; Lu, C.T.; Chang, W.H., Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol, 2006, 26, (2), 128-134.
92. Akbarian, S.; Huang, H.S., Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry, 2009, 65, (3), 198-203.
93. Ernst, C.; Deleva, V.; Deng, X.; Sequeira, A.; Pomarenski, A.; Klempan, T.; Ernst, N.; Quirion, R.; Gratton, A.; Szyf, M.; Turecki, G., Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry, 2009, 66, (1), 22-32.
94. Mellios, N.; Huang, H.S.; Baker, S.P.; Galdzicka, M.; Ginns, E.; Akbarian, S., Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry, 2009, 65, (12), 1006-1014.
95. Sweatt, J.D., Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry, 2009, 65, (3), 191-197.
96. Khojasteh-Fard, M.; Tabrizi, M.; Amoli, M.M., Is DNA methylation responsible for immune system dysfunction in schizophrenia? Med Hypotheses, 2011, 77, (4), 573-579.
97. Dwivedi, Y.; Rizavi, H.S.; Conley, R.R.; Roberts, R.C.; Tamminga, C.A.; Pandey, G.N., Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry, 2003, 60, (8), 804-815. (Pubitemid 36960912)
98. Fuchikami, M.; Morinobu, S.; Segawa, M.; Okamoto, Y.; Yamawaki, S.; Ozaki, N.; Inoue, T.; Kusumi, I.; Koyama, T.; Tsuchiyama, K.; Terao, T., DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One, 2011, 6, (8), e23881.
99. Dong, E.; Nelson, M.; Grayson, D.R.; Costa, E.; Guidotti, A., Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A, 2008, 105, (36), 13614-13619.
100. Sidoli, S.; Cheng, L.; Jensen, O.N., Proteomics in chromatin biology and epigenetics: Elucidation of post-translational modifications of histone proteins by mass spectrometry. J Proteomics, 2012.